{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:40:21Z","timestamp":1784990421342,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation Bettencourt-Schueller"},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejca.2020.11.024","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T04:09:50Z","timestamp":1608869390000},"page":"386-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Nivolumab activity in advanced refractory malignant peritoneal mesothelioma"],"prefix":"10.1016","volume":"144","author":[{"given":"Ondine","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Beaulaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Masliah-Planchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Servois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-8783","authenticated-orcid":false,"given":"Sarah","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.11.024_bib1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","article-title":"Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival","volume":"25","author":"Verma","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2020.11.024_bib2","first-page":"40","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"Janne","year":"2005","journal-title":"Clin Lung Canc"},{"key":"10.1016\/j.ejca.2020.11.024_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejca.2020.11.024_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.11.024_bib5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejca.2020.11.024_bib6","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2020.11.024_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.024_bib8","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.11.024_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2020.11.024_bib10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1101\/gad.973302","article-title":"SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins","volume":"16","author":"Schultz","year":"2002","journal-title":"Genes Dev"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:34:14Z","timestamp":1760733254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920313617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":10,"alternative-id":["S0959804920313617"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab activity in advanced refractory malignant peritoneal mesothelioma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}